Pembrolizumab shows survival benefit for patients with renal cancer
by Elana GotkineFor patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months,
Updated on: May 11,2024
3
Pembrolizumab shows survival benefit for patients with renal cancer
by Elana GotkineFor patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months,
Updated on:May 11,2024
3